Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | PYGB | P11216 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12295132 | 1.00 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL25834664 | 0.92 | CA2 (0.39) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL19726226 | 0.90 | L3MBTL1 (0.38) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13063075 | 0.90 | LGALS1 (0.50) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL16327164 | 0.88 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL18456970 | 0.88 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL18844756 | 0.88 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL1755386 | 0.88 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL13471593 | 0.88 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL15628686 | 0.88 | LGALS1 (0.52) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2011-01-20 | — | — | US | disclosed |
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | GALE, ALPP, UGGT1 | LGALS1 169/4885LGALS3 153/4885LGALS9 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.